Companies in the healthcare market are undertaking various research and development activities to introduce advanced tests for HPV diagnosis. In May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples through a BD diluent tube using BD Onclarity HPV assay. The at-home collection of samples helps address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening.
The CIN & HR-HPVA market in the Middle East & Africa is segmented into the UAE, Saudi Arabia, and South Africa, and the Rest of Middle East & Africa. Saudi Arabia held the largest share of this market in 2021. Further, the market in this region is anticipated to grow at a CAGR of 3.3% during the forecast period. The projected growth in Saudi Arabia is attributed to the low incidence of HPV infection, ranking 12 among all cancers in females, accounting for only 2.4% of all new cases, despite the lack of national screening programs. Also, wide-scale vaccination programs assist in controlling HPV and related infections in the Kingdom, thereby boosting the demand for products and services required for the diagnosis and treatment of this disease.
The Middle East & Africa CIN & HR-HPV treatment market is segmented into disease type, strain type, offering, product type, end user, and country. Based on disease type, the market is subsegmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment registered the largest market share in 2023.
Based on strain type, the market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held the larger market share in 2023.
Based on offering, the Middle East & Africa CIN & HR-HPV treatment market is bifurcated into diagnostic methods and treatments. The treatments segment held the largest market share in 2023. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.
Based on product type, the market is segmented into kits & reagents, instruments, and services. The services segment held the largest market share in 2023.
Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held the largest market share in 2023.
Based on country, the Middle East & Africa CIN & HR-HPV treatment market is segmented into South Africa, Saudi Arabia, the UAE, the Rest of Middle East & Africa. South Africa dominated the market share in 2023.
Fujirebio Europe NV; Qiagen NV; Abbott Laboratories; F. Hoffmann-LA Roche Ltd; and Thermo Fisher Scientific Inc are the leading companies operating in the Middle East & Africa CIN & HR-HPV treatment market in the region.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 534.50 Million |
| Market Size by 2028 | US$ 742.37 Million |
| CAGR (2023 - 2028) | 6.8% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Disease Type
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East & Africa CIN & HR-HPV Treatment Market is valued at US$ 534.50 Million in 2023, it is projected to reach US$ 742.37 Million by 2028.
As per our report Middle East & Africa CIN & HR-HPV Treatment Market, the market size is valued at US$ 534.50 Million in 2023, projecting it to reach US$ 742.37 Million by 2028. This translates to a CAGR of approximately 6.8% during the forecast period.
The Middle East & Africa CIN & HR-HPV Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa CIN & HR-HPV Treatment Market report:
The Middle East & Africa CIN & HR-HPV Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa CIN & HR-HPV Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa CIN & HR-HPV Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa CIN & HR-HPV Treatment Market
